Edward L Tobinick

6379666, Apr 30, 2002

Dec 11, 2000

09/666068

Edward L. Tobinick - Los Angeles CA, 90024-6903

A61K 39395

4241341

A method is disclosed for inhibiting the action of TNF for treating muscular diseases in a human by administering a TNF antagonist for reducing the inflammation of muscle of a human, or for modulating the immune response affecting the muscle of a human by administering a therapeutically effective dosage level to the human of a TNF antagonist.

6419934, Jul 16, 2002

Sep 5, 2000

09/654996

Edward L. Tobinick - Los Angeles CA, 90024-6903

A61K 900

424400, 424422, 424427, 424434, 4241341, 514885, 514898, 514362, 514363, 514364

A method for inhibiting the action of TNF for treating neurological conditions in a human by administering a TNF antagonist for reducing the inflammation of neuronal tissue of said human, or for modulating the immune response affecting neuronal tissue of said human, comprising the step of: administering a therapeutically effective dosage level to said human of said TNF antagonist selected from the group consisting of etanercept, infliximab, and D2E7 (a human anti-TNF mAb from Knoll Pharmaceuticals) for reducing the inflammation of neuronal tissue of said human, or for modulating the immune response affecting neuronal tissue of said human. In addition, for the viral-associated neurological disorders, the following additional step is performed: administering a therapeutically effective dosage level to said human of an antiviral agent or anti-retroviral agents for reducing the inflammation of neuronal tissue of said human, or for modulating the immune response affecting neuronal tissue of said human.

6419944, Jul 16, 2002

Apr 5, 2001

09/826976

Edward L. Tobinick - Los Angeles CA, 90095-6903

A61F 1300

424422, 424427, 424434, 4241301, 4241341, 4241411, 4241421, 4241451, 435 71, 435 78, 514885, 514913, 514914

Cytokine antagonists for use in localized clinical disorders are provided for the treatment and prevention of damage to the optic nerve, other cranial nerves, spinal cord, nerve roots, peripheral nerves or muscles caused by any one of the following: a herniated nucleus pulposus, osteoarthritis, other forms of arthritis, disorders of bone, disease, or trauma. The cytokine antagonists are used to treat these disorders by local administration. These cytokine antagonists include antagonists to tumor necrosis factor; interleukin-1; interleukin-6; and interleukin-8.

6423321, Jul 23, 2002

Dec 27, 2000

09/749189

Edward L. Tobinick - Los Angeles CA, 90024-6903

A61K 900

424400, 424422, 424434, 424427, 4241341, 514898, 514885, 514913, 514914

Specific Cytokine Antagonists, including TNF antagonists and/or Interleukin-1 antagonists, are used as novel therapeutic agents for the treatment of hearing loss, including presbycusis and other forms of sensorineural hearing loss. The present invention provides a method for inhibiting the action of TNF and/or IL-1 antagonists for treating hearing loss in a human by administering a TNF antagonist and/or an IL-1 antagonist for reducing the inflammation affecting the auditory apparatus of said human, or for modulating the immune response affecting the auditory apparatus of said human, by administering a therapeutically effective dosage level to said human of a TNF antagonist and/or an IL-1 antagonist. Administration may be systemic, through the subcutaneous, intramuscular, oral, or intravenous routes; or by delivering an anatomically localized application in the region of the head. The TNF antagonist is selected from the group consisting of etanercept, infliximab, D2E7, CDP 571, or thalidomide; and the IL-1 antagonist is either IL-1 RA or IL-1R type II receptor.

6428787, Aug 6, 2002

Sep 19, 2000

09/665529

Edward L. Tobinick - Los Angeles CA, 90024-6903

A61K 39395

4241341

A method is disclosed for inhibiting the action of TNF for treating conditions of the optic nerve or retina in a human by administering a TNF antagonist for reducing the inflammation of neuronal tissue, or for modulating the immune response affecting neuronal tissue of a human by administering to the human a therapeutically effective dosage level of a TNF antagonist. The TNF antagonist is selected from the group consisting of etanercept, infliximab, pegylated soluble TNF receptor Type I (PEGsTNF-R1), CDP571 (a humanized monoclonal anti-TNF-alpha antibody), and D2E7 (a human anti-TNF mAb) for reducing the inflammation of neuronal tissue of a human, or for modulating the immune response affecting neuronal tissue of a human.

6471961, Oct 29, 2002

May 2, 2000

09/563651

Edward L. Tobinick - Los Angeles CA, 90024-6903

A61K 31495

4241341, 514249, 514323

Interleukin (IL) antagonists are provided for the treatment in humans of neurological disorders, trauma, injuries or compression; neurodegenerative disorders including Alzheimers Disease; demyelinating neurological disorders including multiple sclerosis; retinal disorders; and muscular disorders. The IL antagonists are used to treat these disorders by inhibiting the action of IL in the human body. The administration of these IL antagonists is performed by intrathecal administration; intracerebroventricular administration; intranasal administration; by inhalation; or by alternative routes of administration.

6537549, Mar 25, 2003

Apr 25, 2001

09/841844

Edward L. Tobinick - Los Angeles CA, 90024-6903

A61K 3942

4241341, 424400, 424422, 424427, 424434, 574362, 574363, 574364

Cytokine antagonists for use in localized clinical disorders are provided for the treatment and prevention of damage to the optic nerve, other cranial nerves, spinal cord, nerve roots, peripheral nerves or muscles caused by any one of the following: a herniated nucleus pulposus, osteoarthritis, other forms of arthritis, disorders of bone, disease, or trauma. The cytokine antagonists are used to treat these disorders by local administration. These cytokine antagonists include antagonists to tumor necrosis factor.

6579283, Jun 17, 2003

May 22, 1998

09/083482

Edward L. Tobinick - Los Angeles CA, 90024

A61B 1818

606 9, 606 13, 606 16, 606 10

A laser apparatus for permanently removing a plurality of hair follicles, veins or capillaries from the skin of a patient. The laser apparatus includes a housing having a single laser for sequentially emitting a series of pulses of coherent light energy having a pulse duration in the range of  ms to 10 ms; a fiber optic bundle connected to the laser for transmitting said series of pulses of coherent light energy to the skin of a patient; and a sequence control device for controlling the laser to emit the series of pulses of coherent light energy sequentially, with a time delay of less than 20 milliseconds between the sequential pulses of the single laser. The laser apparatus includes a handpiece assembly for holding a section of the fiber optic bundle for directing the series of pulses of coherent light energy to the same spot of the patients skin to remove the plurality of hair follicles, veins, or capillaries. A method of removing hair or blood vessels from the skin of a patient using a laser apparatus having a single laser, a sequence control device and an optical delivery system, and includes the steps of controlling the single laser to sequentially emit a series of pulses of coherent light energy, transmitting the series of pulses of coherent light energy through the optical delivery system to the same spot on the skin of the patient, irradiating the same spot on the skin containing the hair or blood vessels with the sequential pulses of coherent light energy transmitted through the optical delivery system from the laser, and pulsing the laser at least two times through the optical delivery system at a wavelength in the range of 550 to 1200 nm, at a power level in the range of 1 to 20 Joules/cm , at a pulse duration in the range of  to 10 milliseconds, having a pulse delay in the range of 1 to 20 milliseconds, and having a beam diameter on the treatment area in the range of 4 to 50 millimeters.